Moderna (NASDAQ:MRNA) Raised to Buy at HSBC

HSBC upgraded shares of Moderna (NASDAQ:MRNA) from a hold rating to a buy rating in a report issued on Monday morning, Marketbeat Ratings reports. They currently have $58.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Barclays reduced their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Finally, The Goldman Sachs Group dropped their target price on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $84.00.

Moderna Stock Down 0.9 %

Moderna stock opened at $36.94 on Monday. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47. The business has a fifty day moving average price of $56.98 and a 200-day moving average price of $95.46. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market capitalization of $14.22 billion, a price-to-earnings ratio of -6.35 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the company earned ($1.39) earnings per share. The company’s quarterly revenue was up 3.8% on a year-over-year basis. Equities research analysts forecast that Moderna will post -9.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 13.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,930 shares of company stock worth $217,170. 15.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its position in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP boosted its stake in Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Moderna during the 3rd quarter worth $23,825,000. International Assets Investment Management LLC grew its holdings in shares of Moderna by 10,687.1% during the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after buying an additional 316,552 shares in the last quarter. Finally, Matrix Capital Management Company LP raised its position in shares of Moderna by 60.8% in the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock valued at $77,789,000 after buying an additional 276,000 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.